Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesPreferred Shares IssuedShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catheter Precision (VTAK) Other financing activities (2018 - 2024)

Catheter Precision (VTAK) reported Other financing activities of $309000.0 for Q2 2024, up 270.72% year-over-year from $83351.7 in Q3 2023, and down 51.72% on a QoQ basis from $640000.0 in Q4 2023.

Catheter Precision (VTAK) has 4 years of Other financing activities data on file, last reported at $309000.0 in Q2 2024.

  • Quarterly Other financing activities rose 270.72% year-over-year to $309000.0 in Q2 2024, while the trailing twelve-month figure through Jun 2024 was $949000.0 (up 170.37% YoY) and the FY2023 annual result came in at $640000.0, changed N/A from the prior year.
  • Other financing activities declined to $309000.0 in Q2 2024 per VTAK's latest filing, from $640000.0 in the prior quarter.
  • Across five years, Other financing activities topped out at $872000.0 in Q3 2022 and bottomed at -$1.5 million in Q1 2022.
  • The 3-year median for Other financing activities is $181000.0 (2023), against an average of -$31285.7.
  • The widest annual swing landed in 2023, when Other financing activities jumped 65.26%; it then jumped 270.72% in 2024.
  • Tracing VTAK's Other financing activities over 3 years: stood at $872000.0 in 2022, then slipped by 26.61% to $640000.0 in 2023, then tumbled by 51.72% to $309000.0 in 2024.
  • Per Business Quant, the three latest VTAK Other financing activities figures stand at $309000.0 (Q2 2024), $640000.0 (Q4 2023), and -$181000.0 (Q2 2023).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn
10 Catheter Precision 2.01 Mn 1.20 Mn 390,000.00

Historic Data

Download Data 🔒
DateValue
Jun 30, 2024 309,000.00
Jun 30, 2024 309,000.00
Dec 31, 2023 640,000.00
Dec 31, 2023 640,000.00
Jun 30, 2023 -181,000.00
Jun 30, 2023 -181,000.00
Mar 31, 2023 181,000.00
Mar 31, 2023 181,000.00
Sep 30, 2022 872,000.00
Sep 30, 2022 872,000.00
Jun 30, 2022 -521,000.00
Jun 30, 2022 -521,000.00
Mar 31, 2022 -1.52 Mn
Mar 31, 2022 -1.52 Mn
Dec 31, 2018 2.90 Mn
Dec 31, 2018 2.90 Mn
Sep 30, 2018 526,000.00
Sep 30, 2018 526,000.00